Yong S Lin MD 217 Grand St STE 301, New York, NY 10013 212 226-9717 (phone), 212 226-9723 (fax)
Education:
Medical School Southeast Univ Med Coll, Nanjing, Jiangsu, China Graduated: 1984
Procedures:
Electrocardiogram (EKG or ECG) Nutrition Therapy Pulmonary Function Tests Vaccine Administration
Conditions:
Acne Acute Upper Respiratory Tract Infections Atopic Dermatitis Benign Prostatic Hypertrophy Calculus of the Urinary System
Languages:
Chinese English
Description:
Dr. Lin graduated from the Southeast Univ Med Coll, Nanjing, Jiangsu, China in 1984. He works in New York, NY and specializes in Internal Medicine. Dr. Lin is affiliated with New York Presbyterian Lower Manhattan Hospital.
Cedars-Sinai Medical Center Pain Center 444 S San Vicente Blvd STE 1101, Los Angeles, CA 90048 310 423-9600 (phone), 310 423-9610 (fax)
Education:
Medical School Sun Yat Sen Univ of Med Sci, Guangzhou, China (242 21 Pr 1/71) Graduated: 1982
Languages:
English
Description:
Dr. Lin graduated from the Sun Yat Sen Univ of Med Sci, Guangzhou, China (242 21 Pr 1/71) in 1982. He works in Los Angeles, CA and specializes in Anesthesiology. Dr. Lin is affiliated with Cedars-Sinai Medical Center.
Sanofi
Associate Vp, Clinical Lead of Kevzara , Immunology and Inflammation
Sanofi 2015 - May 2018
Clinical Leader
Sanofi 2011 - Jan 1, 2015
Clinical Study Director
Celgene Jan 1, 2008 - Jan 1, 2011
Clinical Research and Development, Associate Director
Education:
University of Tennessee - Health Science Center College of Medicine
Doctor of Medicine, Doctorates, Medicine
Skills:
Clinical Trials Clinical Development Pharmaceutical Industry Drug Development Clinical Research Clinical Study Design Drug Discovery Rheumatology Gcp Biotechnology Life Sciences Regulatory Submissions Informatics Oncology Ctms Regulatory Affairs Cro Pharmacology
Gerard M. Turino - New York NY, US Yong Y. Lin - Bridgewater NJ, US Shuren Ma - Cliffside Park NJ, US Seymour Lieberman - New York NY, US
International Classification:
C12Q 1/68 C12Q 1/00 G01N 33/00 C12Q 1/02
US Classification:
435 6, 435 4, 436 96, 435 29
Abstract:
The present invention relates to methods of diagnosing and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
Peter H. SCHAFER - Somerset NJ, US Yong Lin - Brooklyn NY, US Donna Sutherland - Green Brook NJ, US
International Classification:
C12Q 1/68 G01N 33/566
US Classification:
435 611, 435 721, 435 724, 435 613, 435 612
Abstract:
Provided herein are the biomarkers for predicting or monitoring the efficacy of a treatment for psoriasis. The use of certain cell markers and mRNA levels as biomarkers to predict whether a psoriasis treatment is likely to be successful is also provided. Further, the expression of these genes or cell markers can be used to monitor progress of treatment effectiveness and patient compliance in psoriasis patients who are receiving treatment.
Methods Of Validating Candidate Compounds For Use In Treating Copd And Other Diseases
Shuren Ma - Cliffside Park NJ, US Yong Y. Lin - Bridgewater NJ, US Seymour Leiberman - New York NY, US
International Classification:
G01N 27/62
US Classification:
435 23, 436 96, 435 29
Abstract:
The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
Compositions And Methods For Treating Rheumatoid Arthritis
- Paris, FR - Tarrytown NY, US Neil GRAHAM - Tarrytown NY, US Yong LIN - Bridgewater NJ, US Janie PARRINO - Tarrytown NY, US Rahul PATEL - Bridgewater NJ, US Janet VAN ADELSBERG - New York NY, US Hubert VAN HOOGSTRATEN - Bridgewater NJ, US
International Classification:
C07K 16/24 A61P 19/02 C07K 16/28 A61K 39/395
Abstract:
The present invention relates to the use of an anti-IL6 receptor antibody in monotherapy for treating rheumatoid arthritis and for improving the physical function and the quality of life of a subject suffering from rheumatoid arthritis.
Methods Of Validating Candidate Compounds For Use In Treating Copd And Other Diseases
- New York NY, US Shuren Ma - Cliffside Park NJ, US Yong Y. Lin - Bridgewater NJ, US Seymour Leiberman - , US
International Classification:
G01N 33/68 H01J 49/00 G01N 27/62 G01N 30/72
Abstract:
The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
Methods Of Validating Candidate Compounds For Use In Treating Copd And Other Diseases
- New York NY, US Shuren Ma - Cliffside Park NJ, US Yong Y Lin - Bridgewater NJ, US Seymour Leiberman - , US
International Classification:
G01N 33/68 G01N 30/72 H01J 49/00
Abstract:
The present invention relates to methods of diagnosing, monitoring, and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry employing an internal standard, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease.
handran, other investigators include: Christine Ambrosone, Gary Zirpoli, Gregory Ciupak, Susan E. McCann, and Zhihong Gong, Roswell Park Cancer Institute; Karen Pawlish, New Jersey State Cancer Registry; and Yong Lin and Kitaw Demissie, The Cancer Institute of New Jersey and UMDNJ-School of Public Health.